Free Trial
NASDAQ:CRVS

Corvus Pharmaceuticals (CRVS) Stock Price, News & Analysis

Corvus Pharmaceuticals logo
$4.13 -0.04 (-0.96%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$4.26 +0.14 (+3.27%)
As of 08/7/2025 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Corvus Pharmaceuticals Stock (NASDAQ:CRVS)

Key Stats

Today's Range
$4.05
$4.24
50-Day Range
$3.73
$4.75
52-Week Range
$2.54
$10.00
Volume
560,150 shs
Average Volume
437,829 shs
Market Capitalization
$281.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00
Consensus Rating
Buy

Company Overview

Corvus Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

CRVS MarketRank™: 

Corvus Pharmaceuticals scored higher than 52% of companies evaluated by MarketBeat, and ranked 567th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Corvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Corvus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Corvus Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.49) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Corvus Pharmaceuticals is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Corvus Pharmaceuticals is -4.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Corvus Pharmaceuticals has a P/B Ratio of 8.10. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Corvus Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Corvus Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    13.17% of the outstanding shares of Corvus Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Corvus Pharmaceuticals has a short interest ratio ("days to cover") of 8.3.
  • Change versus previous month

    Short interest in Corvus Pharmaceuticals has recently increased by 0.90%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Corvus Pharmaceuticals has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Corvus Pharmaceuticals this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    2 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Corvus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,893,541.00 in company stock.

  • Percentage Held by Insiders

    28.50% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    46.64% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Corvus Pharmaceuticals' insider trading history.
Receive CRVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRVS Stock News Headlines

Trump set to Boost Social Security Checks by 400%?
If you're collecting or planning to collect social security... You should see this presentation about President Trump's Executive Order #14196. Legendary investor Louis Navellier believes it could soon not only save Social Security from collapse... But BOOST benefits for millions of retirees by up to 400%. No wonder the financial times called this new initiative...
3 Penny Stocks Wall Street Sees With 243% Upside
See More Headlines

CRVS Stock Analysis - Frequently Asked Questions

Corvus Pharmaceuticals' stock was trading at $5.35 at the start of the year. Since then, CRVS stock has decreased by 22.8% and is now trading at $4.13.

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) announced its quarterly earnings data on Thursday, August, 7th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.13) by $0.03.
Read the conference call transcript
.

Corvus Pharmaceuticals (CRVS) raised $75 million in an initial public offering on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company served as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers.

Corvus Pharmaceuticals' top institutional shareholders include Towerview LLC (0.25%), Empirical Financial Services LLC d.b.a. Empirical Wealth Management (0.25%), Masso Torrence Wealth Management Inc. (0.07%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Peter A Thompson, Richard A Md Miller, William Benton Jones, Leiv Lea and Linda Grais.
View institutional ownership trends
.

Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corvus Pharmaceuticals investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Advanced Micro Devices (AMD), ADMA Biologics (ADMA), Rockwell Medical (RMTI), Axcelis Technologies (ACLS) and Protagonist Therapeutics (PTGX).

Company Calendar

Last Earnings
8/07/2025
Today
8/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRVS
CIK
1626971
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$21.00
Low Price Target
$11.00
Potential Upside/Downside
+263.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$62.29 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.04%
Return on Assets
-13.90%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.90
Quick Ratio
4.90

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
8.10

Miscellaneous

Outstanding Shares
68,170,000
Free Float
48,741,000
Market Cap
$281.54 million
Optionable
Optionable
Beta
0.42

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:CRVS) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners